In past presidential elections, in the year after Election Day, M&A and debt capital markets activity have diverged in their ...
Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week ...
AbbVie (NYSE:ABBV) has agreed to acquire all outstanding equity of neuroscience-focused biotech Aliada Therapeutics for $1.4B ...
AbbVie and Aliada Therapeutics have announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology ...
GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...
Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...
Biotherapeutic firm EvolveImmune Therapeutics gets $65 million upfront and potentially $1.4 billion more if drugmaker AbbVie licenses its T-cell therapy.
AbbVie has inked a deal to work with privately held immuno-oncology company EvolveImmune Therapeutics, to develop therapeutic antibodies for cancer.
AbbVie has announced that it will be acquiring Aliada Therapeutics for $1.4bn, marking a notable boost to its neuroscience ...
Evolveimmune Therapeutics Inc. has secured its fourth big pharma investor and its first pharma development partnership in a deal with Abbvie Inc. The multitarget development deal with Abbvie includes ...
With growth catalysts in place, along with dividend payouts, AbbVie is a good medium to long-term buy. Click here to read an ...